IBX Raises $6M in Placement

Highlights: $6M raised in a heavily oversubscribed placement at 8.5c per share – a 6% discount to the 30-day VWAP. Placement strongly supported by…


New Imaging Technology for Early Detection

Early detection is critical to improving cancer survival rates. Too often, the limitations of today's medical imaging technologies result in cancer being…


Appendix C and Quarterly Activity Report

Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on company activities for the quarter ending 30 September 2020 (Q3…


Quarterly Activity Report and Appendix C

Imagion Biosystems has released their Quarterly Activity Report for the period ended 30 September 2020 and Appendix C. Q3 Highlights Raised $4.7M (after…


Imagion Biosystems Appoints Geoff Hollis as CFO

Imagion Biosystems has appointed Geoff Hollis as Chief Financial Officer. The appointment strengthens the Company’s management and leadership team as the…


HREC Approval for Phase I Study

Imagion Biosystems is pleased to report that it has received approval from the Human Research Ethics Committee (HREC) for the MagSense™ HER2 Phase I study…


CEO Bob Proulx Featured on Biotech2050 Podcast

Earlier this year Imagion Biosystems CEO Bob Proulx was invited to be a guest and record an episode of the Biotech2050 podcast. The COVID-19 pandemic delayed…


Appendix 4D and Half Year Results H1 2020

Imagion Biosystems has announced Appendix 4D and Half Year Results H1 2020. These are the highlights: Significant advancements towards initiating…


IBX Secures Additional Capital — Shareholders Exercise Options

Imagion Biosystems Limited announce that it has received $1.29m for the exercise of unlisted options issued under the terms of the 2018 Rights Issue…


Phase I Study Update: Submission for Ethics Approval Filed

Imagion Biosystems is pleased to provide an update with regard to its plans to undertake a Phase I study of its first MagSense™ product for the detection of…